Platelet-activating Factor Receptor (PAFR) Agonist

Carbamyl-PAF is an analog and agonist of platelet-activating factor (PAF). Carbamyl-PAF is not significantly metabolized by Raji lymphoblasts at 37°C, making it a useful tool for inflammation research. .

1-Palmityl-2-O-acetyl-3-glyceryl phosphorylcholine ((Rac)-PAF (C16)) is an endogenous inflammatory lipid mediator. 1-Palmityl-2-O-acetyl-3-glyceryl phosphorylcholine acts as a high-affinity agonist for PAFR (GPCR), inducing platelet aggregation, vascular permeability, and leukocyte chemotaxis at extremely low concentrations. 1-Palmityl-2-O-acetyl-3-glyceryl phosphorylcholine exerts its effects via cell surface receptors to regulate inflammation.

1-Palmityl-2-O-acetyl-3-glyceryl phosphorylcholine-d₄ ((Rac)-PAF (C16)-d₄) is the deuterium labeled 1-Palmityl-2-O-acetyl-3-glyceryl phosphorylcholine. 1-Palmityl-2-O-acetyl-3-glyceryl phosphorylcholine is an endogenous inflammatory lipid mediator. 1-Palmityl-2-O-acetyl-3-glyceryl phosphorylcholine acts as a high-affinity agonist for PAFR (GPCR), inducing platelet aggregation, vascular permeability, and leukocyte chemotaxis at extremely low concentrations. 1-Palmityl-2-O-acetyl-3-glyceryl phosphorylcholine exerts its effects via cell surface receptors to regulate inflammation.

Butanoyl PAF, a compound closely related to Azelaoyl PC (HY-134154), maintains over 10% of the agonist potency of platelet-activating factor (PAF). Butanoyl PAF's concentration in oxidized low-density lipoprotein surpasses that of enzymatically generated PAF by more than 100-fold.

L-659,989 is an orally active, extremely potent, selective and competitive platelet activating factor (PAF) receptor antagonist.

Butenoyl-PAF is a phospholipid analog of platelet activating factor (PAF-like) that is generated in oxidized low-density lipoprotein (DLDR). Butenoyl-PAF can activate cells that express human PAF receptors, such as neutrophils, monocytes, and platelets, and it stimulates an increase in intracellular calcium ion concentration.

ST-899 is a novel platelet-activating factor (PAF) receptor antagonist. ST-899 can significantly reduce the mortality of mice with endotoxin (LPS)-induced shock. ST-899 can significantly inhibit the increase in serum tumor necrosis factor (TNF) levels induced by LPS, but has no effect on interleukin-6 (IL-6). The regulatory mechanism of ST-899 is to block the positive feedback loop between PAF and TNF, thereby reducing the inflammatory response. ST-899 can be used to study inflammatory diseases such as septic shock.